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Abstract
Background: Implementing treatments and interventions with demonstrated effectiveness is critical for improving
patient health outcomes at a reduced cost. When an evidence-based intervention (EBI) is implemented with fidelity
in a setting that is very similar to the setting wherein it was previously found to be effective, it is reasonable to
anticipate similar benefits of that EBI. However, one goal of implementation science is to expand the use of EBIs as
broadly as is feasible and appropriate in order to foster the greatest public health impact. When implementing an
EBI in a novel setting, or targeting novel populations, one must consider whether there is sufficient justification that
the EBI would have similar benefits to those found in earlier trials.
Discussion: In this paper, we introduce a new concept for implementation called “scaling-out” when EBIs are
adapted either to new populations or new delivery systems, or both. Using existing external validity theories and
multilevel mediation modeling, we provide a logical framework for determining what new empirical evidence is
required for an intervention to retain its evidence-based standard in this new context. The motivating questions are
whether scale-out can reasonably be expected to produce population-level effectiveness as found in previous
studies, and what additional empirical evaluations would be necessary to test for this short of an entirely new
effectiveness trial. We present evaluation options for assessing whether scaling-out results in the ultimate health
outcome of interest.
Conclusion: In scaling to health or service delivery systems or population/community contexts that are different
from the setting where the EBI was originally tested, there are situations where a shorter timeframe of translation is
possible. We argue that implementation of an EBI in a moderately different setting or with a different population
can sometimes “borrow strength” from evidence of impact in a prior effectiveness trial. The collection of additional
empirical data is deemed necessary by the nature and degree of adaptations to the EBI and the context. Our
argument in this paper is conceptual, and we propose formal empirical tests of mediational equivalence in a
follow-up paper.
Keywords: Scaling-out, Scaling-up, Delivery system fixed, Population fixed, Implementation science, Evidence-based
intervention, Intervention adaptation, External validity, Multilevel mediation modeling, Effectiveness, Mediational
equivalence
* Correspondence: gaarons@ucsd.edu
1Department of Psychiatry, University of California, San Diego, La Jolla, CA,
USA
2Child and Adolescent Services Research Center, San Diego, CA, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Aarons et al. Implementation Science  (2017) 12:111 
DOI 10.1186/s13012-017-0640-6
Introduction
One goal of implementation science is to expand the use
of evidence-based interventions (EBIs) appropriately and
as broadly as feasible in order to foster the greatest public
health impact [1]. This goal of generalizing the use of EBIs
to improve public health is rooted in theory regarding ex-
ternal validity, first introduced approximately 60 years ago
by Campbell [2]. In Campbell’s definition, external validity
concerns the representativeness or generalizability of an
effect and asks: to what populations, settings, and out-
comes can an empirically established causal association
between an intervention and outcome be generalized? Fol-
lowing this original formulation, Cook and Campbell [3]
and Cronbach [4] specified domains wherein a causal as-
sociation can be examined with respect to generalizability:
the population where it is delivered, the intervention, out-
comes, and settings. In this paper, we introduce a new
concept for implementation called “scaling-out” where
EBIs are implemented with either new populations, new
delivery systems, or both. Using existing external validity
theories and multilevel mediation modeling, we provide a
logical framework for determining what new empirical
evidence is required for an intervention to retain its
evidence-based standard in this new setting. The goal of
this paper is to present a conceptual approach to evaluat-
ing the spread and generalization of EBIs across health
and allied health service systems within these domains.
When an EBI is implemented with fidelity in a setting
that is identical to or very similar to where it was previ-
ously tested and found to be effective, it is reasonable to
anticipate that the EBI would provide similar benefits to
those found earlier. However, every EBI implementation
raises two critical questions: (1) is there sufficient empir-
ical evidence or justification from prior evidence that this
EBI would impact health as expected, and (2) whether sys-
tem, organization, and/or EBI adaptations are necessary,
sufficient, and culturally and organizationally appropriate
to make it feasible, practical, and acceptable in the new
context. We argue first that EBI implementation in a
moderately different setting or with a different population
can sometimes “borrow strength” from evidence of impact
in a prior effectiveness trial with additional empirical data
deemed necessary by the nature and degree of adapta-
tions. This strategy of testing precise elements in a medi-
ation model can be seen as an extension of Cook’s five
pragmatic principles for justifying generalized causal infer-
ences to different target populations and settings [5]. We
argue that adaptations to populations or delivery systems
require that some new empirical evidence is often neces-
sary to retain evidentiary status, and we lean on mediation
modeling to make this case. While our argument in this
paper is conceptual, we propose formal statistical ap-
proaches and empirical tests of mediational equivalence in
a follow-up methods paper.
Defining a new concept for
implementation—“scaling-out”
We define the approach to adapting and delivering EBIs
across health and allied health service systems and orga-
nizations and/or across different target populations as
scaling-out. Scaling-out is the deliberate use of strategies
to implement, test, improve, and sustain EBIs as they are
delivered in novel circumstances distinct from, but
closely related to, previous implementations. Although
we propose an approach that identifies three types of
scaling-out, we focus on two major types of scaling-out
in this paper, (1) one that involves delivery of an inter-
vention to the same target population as previously
tested, but through different settings or delivery systems,
and (2) one that involves delivering an intervention to a
different population than previously tested, but through
similar settings or delivery systems. The motivating
questions are whether scaling-out can reasonably be ex-
pected to produce population-level effectiveness as
found in previous studies, and what additional empirical
evaluations would be necessary to test for this short of
an entirely new effectiveness trial. If testing of this new
scale-out requires the full empirical evaluation that
would be required for establishing an EBI, this would be
exceptionally costly, time consuming, and would delay
implementation, especially to populations underrepre-
sented in scientific trials or in settings where its delivery
could reasonably produce benefit. Indeed, if we can le-
gitimately borrow strength from previous studies and a
modest amount of empirical evidence, this could acceler-
ate and expand benefit to populations that have experi-
enced health disparities that might never be included in
a rigorous randomized effectiveness trial [6].
Scaling-out vs scaling-up
The words “scaling,” “scale-up,” or “scaling-up” have
clear meaning and importance in implementation sci-
ence. In scaling-up, an EBI designed for one setting (e.g.,
a public mental health clinic) is expanded to other
health delivery units within the same or very similar set-
tings under which it has been tested (e.g., a statewide
roll-out to all its public mental health clinics). An ex-
pectation of beneficial impact when scaling-up relies
upon Cook’s principle of proximal similarity [5] because
a nearly identical intervention is delivered in the same
way to a similar population. Often when scaling-up an
EBI to a large number of subjects by an expanded num-
ber of service delivery organizations, policy-makers and
researchers are willing to assume that health outcomes
will be improved as long as the EBI is implemented well
[7]. Often, funders rely on this assumption without pro-
viding support for continuing evaluation for verification
of impact. This minimalist perspective places a heavy re-
liance on previous tests of effectiveness and minimizes
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the importance of evaluations of implementation outcomes
(e.g., self-reports of high fidelity). However, this perspective
is not universally shared [8], and there are examples of EBI
scale-ups where health outcomes did not improve as
intended [9]. In some settings, policy-makers and system
leaders want to know: will it (the EBI) work here for our cit-
izens? Provided sufficient qualitative and quantitative data
are available, modern implementation science evaluations
can often be used to assess why expected implementation
outcomes did or did not occur [10].
In contrast to this perspective on scaling-up, we use
the term scaling-out to refer to specific variants in
implementing an EBI, policy, or set of programs that are
evidence-based. As shown in Table 1, we propose three
types of scaling-out; the first variant, type I: population
fixed, different delivery system, involves targeting the
same population as previously tested, but through a dif-
ferent delivery system, the second type of scaling-out,
type II: delivery system fixed, different population, in-
volves targeting a different population than previously
tested, but through the same delivery system, and the
final type of scaling-out, type III: different population
and delivery system, involves targeting a different popu-
lation, through a different delivery system, as compared
to the original EBI trial. In all variants of scaling-out,
there is more concern about the impact on effectiveness
and health outcomes, as there is more uncertainty
whether the empirically supported causal association be-
tween intervention and outcome found in previous studies
will hold when adapted and tested under yet-unstudied
conditions. As a result, with scaling-out we are unable to
rely completely on findings of previous studies.
We present a logical argument regarding the degree of
empirical evidence needed for scaling-out that extends
beyond the trials that established the original evidence
of impact. Though we introduce three types of scaling-
out, we focus on types I and II scaling-out in this paper,
wherein either the target population or delivery system
remains fixed, respectively. We note that the logic be-
hind borrowing strength from previous studies requires
that we justify that key elements of the intervention still
exist and are delivered with fidelity, that the delivery sys-
tem retains critical components of the implementation
strategy, and that broader ecological systems are still
supportive of the delivery and sustainment of this inter-
vention. We describe four levels of evidence and recom-
mend that evidence of the effectiveness of scaling-out
can be supported if we establish that mediational path-
ways have equivalent strength as they did in the original
trials.
Empirical evidence needed for scaling-out
In one sense, the concept of scaling-out of an EBI is
analogous to off-label use of a pharmaceutical that has
been approved for patients having a specific indication.
For example, the US Food and Drug Administration’s
(FDA) and other regulatory agencies’ limited approval of
medications to be used for specific conditions is
Table 1 Key terms and definitions for the scale-out of an
evidence-based intervention (EBI)
Key term Definition
Scale-up The deliberate effort to broaden the
delivery of an EBI with the intention of
reaching larger numbers of a target
audience. Often an EBI scale-up will
target health delivery units within the
same, or very similar settings, under
which the EBI has already been tested.
Scale-out A deliberate effort to broaden the
delivery of an EBI. Scale-out is an ex-
tension of scale-up and uniquely refers
to the deliberate use of strategies to
implement, test, improve, and sustain
an EBI as it is delivered to new popula-
tions and/or through new delivery sys-
tems that differ from those in
effectiveness trials. There are three
types of scale-out, each indicating the
extent to which the EBI is delivered to
new populations and/or through new
delivery systems.
Type I scale-out: population
fixed, different delivery system
A type of scaling-out wherein an EBI is
scaled-out to the same population as
previously tested, but through a differ-
ent delivery system.
Type II scale-out: delivery sys-
tem fixed, different population
A type of scaling-out wherein an EBI is
scaled-out to a different target popula-
tion through the same delivery system
as previously tested.
Type III scale-out: different
population and delivery system
A type of scaling-out wherein an EBI is
scaled-out to a different target popula-
tion, through a different delivery sys-
tem, than previously tested.
Borrowing strength Utilizing empirical evidence from a
previous EBI effectiveness trial in
combination with new evidence from
a scale-out trial to test EBI effective-
ness when moving it to a new popula-
tion and/or through a new delivery
system. Borrowing strength allows for
a more limited evaluation, typically pri-
oritizing implementation outcomes,
that takes less time and expense to
conduct than the original effectiveness
trial.
Intervention adaptation Modifications to an EBI to facilitate its
feasible, practical, and acceptable
implementation in new contexts.
External validity The representativeness or
generalizability of an effect.
Core elements Prototypical and/or necessary activities
or components of an EBI. When
scaling-out an EBI to a new population
and/or through a new delivery system,
core elements of the EBI should be
retained to ensure its effectiveness.
EBI evidence-based intervention
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designed to give strong assurance of what patients and
physicians can expect under these limited settings. Ex-
cept for specified contraindications, it is not illegal to
prescribe FDA-approved drugs outside these settings
(i.e., off-label usage) or at different dosages than origin-
ally approved. However, no assurance is given for their
effectiveness upon doing so; there are no assurances of
their safety, or that iatrogenic effects will be absent.
Similarly, EBIs that are tested for effectiveness in one
setting have some assurance of impact when scaled-up
to health units and subjects in very similar settings. But
we would have less confidence about the potential health
impact of an EBI when scaled-out to different settings or
populations. Intuitively one would expect that the more
similar the delivery system, the broader the contextual
setting, the intervention, and the population, the more
we should be able to rely on previous evidence, and the
less new empirical evidence should be needed, to antici-
pate a successful scaling-out.
But exactly what is the degree of “borrowing strength”
from previous research studies that we would want to
rely on? When is it justified to expect the same or simi-
lar impact of an EBI in this new setting? What new ef-
fectiveness testing should be required when an EBI is
moved to different setting or population? What similar-
ities exist in the mechanisms of action in the scaling-out
compared to that previously found? When is it legitim-
ate from a causal inference perspective to combine pre-
viously collected effectiveness and mechanistic
evaluation data with new evaluation data on the scaled-
out version? When would an entirely new effectiveness
trial be required for a scaling-out to re-establish the
existing standard of evidence?
To answer these questions, we begin with Cook’s con-
ceptual principles of proximal similarity and heteroge-
neous irrelevancies [5]. Proximal similarity points to the
degree that the scale-out contexts are similar to previous
studies. A high degree of similarity engenders greater
confidence that the health impact in the new context
would be similar to what was found in previous studies.
Heterogeneous irrelevancies refer to the robustness, or
invariance, of a causal association across substantively ir-
relevant conditions. As noted by Matt and colleagues
[11], “The greater the range of substantive irrelevancies
across which a causal association has been found to be
robust, the more confident one can be that the causal
association will hold under yet-unstudied conditions”
(p. 524). We propose criteria regarding when to turn
these qualitative comparisons into empirical tests.
In our view, one must either establish or be willing to
accept the following similarities between scaling-out and
previous research. First, even as the EBI is adapted to
new settings or populations, it still must retain its core
elements [12]. Second, the underlying mechanism of
action regarding how core elements affect health out-
comes remains the same, which relies on analyses of
such mechanisms [13]. Third, there must be sufficient
organizational or system support to deliver the intervention
as intended to sufficient numbers of the target population.
Logically, we have no justification to anticipate health
impact in scale-out if we are unwilling to embrace these
three fundamental premises either based on the strength of
generalizability of existing evidence or new data. Because
scaling-out involves changes in the delivery system and/or
population, and typically requires relevant EBI adaptation
and/or context adaptation, we propose that an explicit
mediation model be tested for equivalence to previous ones
that established the intervention’s evidence [14].
Two types of scaling-out: population fixed, different
system, and delivery system fixed, different
population, scaling-out
Here we emphasize two distinct types of scaling-out,
“Type I: population fixed, different delivery system” and
“Type II: delivery system fixed, different population” that
we argue have potential for retaining their evidence-
based status provided they also satisfy what we call “me-
diational equivalence” (discussed in greater detail below).
In the discussion, we contrast these with both a typical
scaling-up, wherein both the population and delivery
system remain fixed, and the more complex scale-out,
type III, wherein both the population and delivery sys-
tem are different than originally tested.
Type I: population fixed, different delivery system
scaling-out
We formally define type I: population fixed, different de-
livery system scaling-out as implementation where an
EBI is delivered through a different delivery system to
the same population where it has previously been tested.
This type of scaling-out pursues an alternative avenue to
reach its target population. As an example, a number of
evidence-based parent training programs have been
tested and found to be effective in universal, selective,
and indicated prevention trials [15–17]. Most of these
programs have been tested and delivered in schools [18],
mental health, or social services systems [19] but may
have greater reach through alternative delivery systems.
The first of two examples type I scaling-out involves the
delivery of the SafeCare® child maltreatment intervention
using an “interagency collaborative team” implementa-
tion strategy across one large (i.e., population = 3.2 mil-
lion) county in the US [20]. In scaling-out SafeCare, a
new interagency “seed team” was formed from diverse
stakeholders that became the source of knowledge,
model expertise, and leadership that allowed this EBI to
be delivered with fidelity and to be sustained over time.
The second example involves the delivery of Familias
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Unidas, a parenting program for Hispanic families with
young adolescents, which was originally designed to be
housed in middle schools [21–23]. Familias Unidas has
been shown to have its strongest effect with Hispanic
families with poor parent-child communication [24, 25],
and it is this population that could be engaged through a
different system than the school. Under policy mecha-
nisms such as the US Affordable Care Act’s expanded
access to health care in the US [26], there is an oppor-
tunity for Familias Unidas and similar EBIs to be access-
ible free of charge to the same types of families through
primary care settings [27, 28]. Thus, health care system
changes may provide an important opportunity for type
I scaling-out. Because few effectiveness trials of these
programs exist in primary care, the evidence for the ef-
fectiveness of such parenting programs while being de-
livered through primary care is relatively limited [29]. If
we could legitimately build on the large effectiveness
trial knowledge that already exists regarding these par-
enting programs, we could accelerate the research that
supports delivery of such programs through primary
care.
Successful implementation of these parenting inter-
ventions within primary care would require a
reorganization to screen and refer families as well as to
integrate, co-locate, or establish formal agreements be-
tween service systems, agencies, or community-based or-
ganizations that can deliver such programs effectively. In
addition, type I scale-out may require important changes
in how the intervention is delivered. For example, the
Familias Unidas training program has been delivered by
facilitators in small parent group meetings as well as in
the home with individual families. SafeCare is delivered
in the home where parents can learn and practice skills
in vivo. A parenting program that is initiated by primary
care may need to replace such group and home delivery
modalities. This may be facilitated through the support
of more logistically efficient technologies and content,
such as interactive content about parenting viewable
through tablets in primary care waiting rooms and vir-
tual groups, having mock home environments within the
primary care setting, or use of technology for parents to
practice in their homes with coaches to work with them
remotely. These sessions would support parents in prac-
ticing skills related to child safety, health, and parent-
child interactions.
A final example of type I scaling-out is the delivery of
pre-exposure prophylaxis (PrEP) to populations at high
risk of HIV infection. In international and domestic clin-
ical trials, adherence to PrEP medication has been dem-
onstrated to reduce the risk of HIV infection by close to
90% among adult sero-negative men and women whose
partners were infected with HIV and at-risk adult men
who have sex with men, populations for whom federal
guidelines released by the Centers for Disease Control
and Prevention (CDC) recommend use of PrEP [30]. In
order to expand the use of PrEP, clinics serving these
populations that conduct HIV/STD testing and treat-
ment are emerging as sites for offering and/or delivering
PrEP. However, PrEP delivery requires a higher level of
engagement of healthcare providers than has typically
been engaged for HIV primary prevention; in fact, it
more closely mimics the types of care an individual liv-
ing with HIV received than the less medicalized services
more typically provided for HIV prevention. Staffing,
training, and costs required to deliver PrEP in this set-
ting are complex and need to be addressed for successful
implementation in STD clinics [31].
Type II: delivery system fixed, different population
scaling-out
We define type II: delivery system fixed, different popu-
lation scaling-out as implementation that extends the
reach of an existing intervention to a novel population
within a similar service system. Type II scaling-out uses
the same delivery system but aims to reach a different
population of individuals, groups, or families for which
the intervention has not yet been tested. For example, a
smoking cessation approach originally tested with behav-
ioral health patients may be implemented for those with
diabetes in the same managed care health system. How-
ever, populations may also vary by race or ethnicity, cul-
tural heritage, and considerations would have to
determine what core elements must be retained and
what might be adapted.
A large literature exists on cultural adaptation of
evidence-based interventions [32, 33]; many of these are
examples of scaling-out, as often the delivery system is
held constant. There already exist several approaches to
surface and deep structure adaptation to different popu-
lations [34], and the framework in this paper can com-
plement these approaches by identifying particular
components to test empirically.
PrEP delivery for adolescents is an example of a type II:
delivery system fixed, different population scaling-out im-
plementation. The CDC PrEP guidelines [30] did not pro-
vide a recommendation for the use of PrEP for at-risk
adolescents due to lack of evidence of efficacy and safety
for this population at the time the guidelines were devel-
oped. However, adolescents between the ages of 13–19
who engage in risky sexual behavior and/or injection
drugs are also at increased risk of HIV infection, and
accounted for 4% of new HIV diagnoses in 2015. Recog-
nizing this potential risk, health care providers have begun
to deliver PrEP for adolescents. Given that state laws and
regulations vary in terms of parental consent requirements
for medical services, PrEP implementation in this new
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population requires different strategies and research that
can inform effective delivery [35–37].
Evaluation options for scaling-out
EBI replicability or effectiveness
When scaling-out, having metrics to test specifically
whether expected outcomes improve are important;
however, we suggest that there are instances where it
may not be necessary to include all, or even any of the
health outcomes that might be included in an efficacy or
effectiveness trial. To assess whether a scaled-out ver-
sion has impact on the ultimate health outcome or distal
target of interest, we propose an efficient evaluation that
tests a limited set of means and relationships, and com-
bines new data with evidence from previous trials. Typ-
ically, a more limited evaluation would collect a small
amount of—or even no—health outcome data, but a
substantial amount of implementation process and out-
put data, what others have called implementation out-
comes [10]. It would therefore take far less time and
expense to conduct such an evaluation compared to the
original effectiveness trial.
Levels of evidence for scale-out evaluations
As shown in Table 2, we have identified four levels of
evidence that could be applied to predict or measure the
expected health impact of implementing an EBI. In this
table, the columns refer to major domains of the RE-
AIM model that have long been recognized as critical in
producing population-level effects [38]. Contents of
other columns provide examples of potential constructs
of interest. The empirical data in these implementation
studies range from no new data in level 0, to a complete
replication trial that again supports EBI effectiveness in
level 3. Level 0 depends almost exclusively on the as-
sumption that the new implementation will follow in the
same footsteps as the previous intervention did when it
produced findings of health impact. With a lack of em-
pirical data in the new setting, the burden of proof ne-
cessarily rests on similarity with previous work. Level 1
involves proxy or indirect measures of the key RE-AIM
components and is intended as an inexpensive large-
scale implementation evaluation. Level 2 focuses on
demonstrating that key theoretical mediators or mecha-
nisms work as expected. Finally, level 3 involves a full-
scale randomized study such as a type 2 hybrid trial that
tests both effectiveness and implementation [39]. We
note that an actual design may involve different levels of
assessment across the columns. For example, it may be
appropriate to use a full randomized trial to assess a
proxy outcome (e.g., level 3) while not measuring the
ultimate or distal health outcome (level 0).
Table 2 Four levels of evidence for evaluations and examples in scaling-out an evidence-based intervention (EBI)
Level Of
evidence
Implementation
fidelity
(Implementation
strategy delivered
as intended)
Intervention
fidelity
(Clinical or health
intervention
delivered as
intended)
Reach and
exposure
Adoption Sustainment Effect on
health
outcome
Potential use
0: minimal
or no new
empirical
evidence
Not measured Training
certification of
facilitator and/or
clinician prior to
new
implementation
Numbers of
individuals
exposed
Attendance of
organizational
representatives at
trainings
Not measured Not
measured
Demonstration
program that
explicitly follows an
intervention manual
1. Proxy
empirical
evidence
Leadership and
staff self-efficacy to
support EBI
Facilitator and/or
clinician ; self-
assessment of
fidelity
Attendance
for behavioral
intervention;
filled
prescriptions
Formal
acknowledgment
by organizations
of adoption
Completion of
yearly reports by
implementing
agencies
Assessment
of
intermediate
and/or
proximal
health
outcome
Inexpensive large-
scale implementation
evaluation
2. Direct
empirical
evidence
Measurement of
milestone
attainment; speed,
quality, and
quantity of
implementation
Independent
assessment of
fidelity
Ratings of
quality of
behavioral
homework,
medication
adherence
Quality of staff
training
Sustained number
of staff and
number of subjects
exposed to
intervention with
fidelity
Change in
primary
health
outcome
from baseline
Formal
implementation
evaluation to
establish evidence
base through
mediational
mechanisms
3. Full
randomized
hybrid trial
Evaluate
intervention
vs
comparison
on primary
outcome
Type II hybrid trial to
directly establish full
evidence base
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Sequential mediating model for assessing EBI effectiveness
To examine when such a limited evaluation design for
scaling-out would be sufficient to judge whether the EBI
retains effectiveness, we consider a simplified sequential
mediational model presented in Fig. 1. This figure pro-
vides a schematic view of the major domains to examine
regarding whether a clinical/preventive intervention that
has been judged to be evidence-based within one setting
would be expected to have similar effects when scaled-
out. On the left, a specific clinical/preventive interven-
tion is embedded in a health delivery system and eco-
logical context including characteristics of the
population, local communities, and macro system [40].
In scaling-out, the intervention and/or context could be
adapted and either the health delivery system/commu-
nity context or population is different from that in which
it was originally tested. At the top right of this figure are
two factors central to health outcomes from a delivery
perspective: fidelity of the implementation process
known as “implementation fidelity” (e.g., training, super-
vision, incentive structure, and informatics) [41] and fi-
delity to the clinical/preventive intervention itself known
as “intervention fidelity” (or more generally this includes
adherence to the intended program content, and respon-
siveness, quality and competence in delivering the pro-
gram [42, 43]). Next is the degree of uptake by the
target population (e.g., the reach into the target commu-
nity and the degree of exposure to, or usage of the clin-
ical/preventive intervention). Following this in sequence
are the proximal behavioral outcomes (e.g., changes in
parent-child communication, medication adherence, and
selection of evidence-based prevention programs that
match community needs) and the ultimate health out-
comes (e.g., reduced HIV infections for PrEP or parent-
ing skills, children’s cognitive, affective, or behavioral
health for parenting programs) [6]. The Greek letters in
this figure indicate the strength of relationships between
the steps in this mediational sequence, and the Roman
letters represent mean levels achieved for each of these.
Assuming a conceptual theory of mediation holds
for scaling-out
Cook’s principle of causal explanation [5] requires inves-
tigation into the causal mediating mechanisms that
underlie a relationship of interest, explaining how and
why an effect occurs. Complete understanding of a
causal mediating process can strengthen generalized
causal inference by providing information on when and
where an effect can be replicated. As one example, im-
provement in the parent-child relationship through par-
enting interventions has been shown to relate to lower
drug abuse, HIV sex risk behavior, and internalizing be-
havioral symptoms for adolescents [24, 44–46]. Thus,
the parent-child relationship can serve as a proximal
mechanism or intermediate outcome on the pathway to
improved behavioral health. In delivering PrEP to pre-
vent HIV incidence, adherence to the medication would
be the most important intermediate outcome. Assuming
the conceptual theory of mediation holds in a scaled-out
adaptation, relying on Cook’s principles of heteroge-
neous irrelevancies and proximal similarity, then we
could assess impact on the mediating variable using a
Fig. 1 Schematic of scaling-out and implementation and effectiveness domains for evaluation
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level 1 design for assessing a proxy outcome. We can
also infer that positive effects would be expected to
translate into corresponding benefit on the distal out-
come as well. Following up the example of Familias Uni-
das interventions, Perrino and colleagues tested the
impact of this intervention in an integrative synthesis
analysis on three populations ranging from a general
population (universal prevention) to one with moderate
risk (selective prevention) and more serious individual
level risk (indicated prevention) [24]. They found that
the theoretical mediator of parent-child communication
was impacted only when its baseline measure was low.
Therefore, it would be reasonable to expect beneficial
outcomes from this intervention when an intervention
increases the mean on parent-child communication to
the level found in previous studies.
Considerations for scaling-out
Intervention adaptation
For all types of scaling-out, it may be possible to use the
identical EBI (e.g., delivered using the same manualized
version and/or dosage). However, we more often need to
adapt the intervention to fit the new population and/or
new delivery system. To further describe the adaptations
that need to occur during scaling-out, we build on com-
monalities that are present in three implementation
frameworks, the Exploration, Preparation, Implementa-
tion, Sustainment (EPIS) framework [47], the Dynamic
Sustainability Framework [40], and the Consolidated
Framework for Implementation Research (CFIR) [48]. In
addition, the EPIS framework led to the development of
the Dynamic Adaptation Process (DAP) that provides a
process for pre-assessment, convening an “implementa-
tion resource team” to guide the implementation
process, and use of audit and feedback data to help
guide appropriate EBI adaptation [49]. The important
commonalities across these frameworks are that they all
address outer policy and system context, inner
organizational context where services are delivered, and
characteristics of the EBI itself. Thus, for successful
scaling-out an EBI, we focus on three key interconnected
implementation/sustainment components: (1) the align-
ment of the surrounding ecological context including
characteristics of the target population as well as broader
cultural and contextual factors (e.g., policies, funding),
(2) the alignment of the health or service delivery system
and organizations where it is delivered, and (3) the in-
tegrity of the EBI itself as adaptations occur. These three
components often evolve through external forces (e.g.,
national health system policy reform and/or reim-
bursement), change in response to interactions during
scaling-out (e.g., a children’s hospital hires community
outreach workers to deliver a new EBI in high-need
communities), or change when an EBI is adapted to
patients or clients (e.g., making an intervention accept-
able to those with a different cultural background).
Concern regarding the effectiveness of an interven-
tion when adapted has been addressed for a number
of specific EBIs, including child maltreatment inter-
ventions [50], substance abuse treatment [51], child
anxiety interventions [52], HIV treatment [53],
school-based social competence interventions [54],
psychological treatments for a variety of disorders [55,
56], and health risk prevention programs [57–59].
However, there is mounting evidence that overly strict
intervention fidelity may be at odds with effective im-
plementation of EBIs in real-world practice settings
(i.e., outside of highly controlled efficacy trials), thus,
raising concern about the balance between delivering
EBIs with fidelity and making adaptations believed to
be necessary for usual care contexts. This “adapta-
tion-fidelity” tension is a critical component of
scaling-out in that it is addressed head on as pro-
posed in more dynamic models of implementation
process [60–62]. However, new approaches to identi-
fying and coding EBI modifications and adaptations
are promising in regard to rigorous study of adapta-
tions and their impacts [63]. Scaling-out, while allow-
ing for appropriate system, organization, and
intervention adaptation, necessitates a better under-
standing of how to facilitate delivery of EBIs with ap-
propriate content adherence and competence in
delivery, while allowing for adaptations to facilitate ef-
fective uptake and spread, and that do not interfere
with core elements (i.e., intervention components be-
lieved to be necessary to attain intervention effects).
Core elements of the intervention
One of the first steps in scaling-out is to delineate the core
elements of the EBI to be implemented. We define core
EBI elements as activities or components of an interven-
tion that are necessary in order to obtain the clinical or
public health outcomes [58, 64–66]. If core elements are
well-defined then it is possible to determine what is and
what is not adaptable [48] (at least for the EBI). To have
maximum positive impact, any adaptations of an EBI to a
new context should retain the core elements and add or
modify components that complement, and do not conflict
with existing ones. This concept of retaining core ele-
ments to facilitate generalization of impact is consistent
with Cook’s (1991) principle of proximal similarity [5].
Under this principle, generalization is justified when all
relevant properties of the causal association, such as
prototypical and necessary components of an EBI, are ad-
equately represented in the new context. Reciprocally,
knowledge of irrelevant components of an EBI also facili-
tates decisions regarding adaptations to fit a new context.
This is consistent with Cook’s principle of heterogeneous
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irrelevancies that suggests the greater the range of sub-
stantive irrelevancies across which a causal association has
been found to be robust, the more confident one can be
that the causal association can be generalized to yet-
unstudied conditions. Discussions of this issue most com-
monly pertain to adaptations to fit an EBI for a particular
cultural group [58]. However, adaptations to accommo-
date an EBI are likely to be needed at the service system
or organization levels, and often to the EBI itself [47, 60].
The less system/organization adaptation needed, the more
readily an EBI can be assimilated. However, systems and
organizations may need to adapt or accommodate and
change in order to implement and sustain a given EBI. In
our framework, the existence of multiple trials that pro-
duce similar health outcomes, such as one finds in a syn-
thesis of preventive trials focused on child depression [67],
makes for a higher expectation of health impact when a
scaled-out intervention shows comparable intervention
and implementation fidelity and reach as in previous
studies.
Discussion
In this paper, we introduced and defined a new concept
for implementation called scaling-out. Scaling-out pro-
vides an opportunity to use a strategic approach to im-
prove the efficiency of moving an EBI from one setting
to another and/or from one population to another.
When scaling-out an EBI in a moderately different set-
ting or with a different population, we suggest it is
sometimes possible to “borrow strength” from evidence
of impact in a prior effectiveness trial with additional
empirical data deemed necessary by the nature and de-
gree of adaptations. We take a mechanistic approach in
suggesting that by testing underlying mechanisms or
mediators of effects, the efficiency of testing EBIs for
new populations or new service systems can be stream-
lined through a greater understanding of and use of
prior data to borrow strength from previous effective-
ness studies.
Scaling-out
We have focused primarily on two types of scaling-out
in this paper for a single EBI and recommended different
levels of empirical tests involving key mediators that
would provide some assurance that the scaled-out im-
plementation would produce its intended effects. Similar
scaling-out approaches are possible when implementing
other types of interventions including evidence-based
decision support systems, such as Communities that
Care [68–72], which helps communities decide which
among a menu of EBIs are most appropriate to imple-
ment, rather than a single intervention. We only men-
tion the important and more complex type III scale-out,
wherein both the delivery system and the population are
different than in initial efficacy studies. For example, in-
terventions to prevent mother to child HIV transmission
(PMTCT) that are moved from clinic-based to
congregation-based services in different countries or ser-
vice systems could engage different populations that
were not included in previous trials [73]. It seems nat-
ural to require much more evidence when both popula-
tion and delivery system change; doing so would
demand new empirical evidence beyond that for either
delivery system or population fixed scaling-out.
The notion of level of similarity of a population or de-
livery system is an important consideration. Take type I
scale-out first, wherein the population remains fixed and
the delivery system is different. Type I scale-out will re-
quire implementers to develop ways in which population
differences may be minimized. Inclusion/exclusion cri-
teria for those to receive a given EBI could be utilized to
clearly (as much as possible) define the service popula-
tion. For example, adolescents with juvenile justice sys-
tem involvement, a substance use disorder, and of a
similar cultural background could be identified. For type
II scale-out, wherein the delivery system is fixed, though
the target population is different, there also could be
multiple approaches. For example, San Diego County
Mental Health and Los Angeles county Mental Health
are both large public sector service systems operating
within the same state in the US. They both provide ser-
vices to a large extent through some direct service
provision, but primarily provide services through pro-
curement and contracting with community-based orga-
nizations to provide direct services to children and
adolescents. While these systems do share some similar-
ities, there are also some differences in regard to their
procurement and contracting processes.
For different types of scaling-out, we propose a logical
framework that researchers and policy-makers can use
to assert conditions under which an established se-
quence of mediational elements described in Fig. 1 could
(a) be expected to hold in the absence of new data, (b)
be ascertained by new proxy or direct empirical evidence
that their mean values are equivalent to that from previ-
ous studies (Roman letters in Fig. 1), or (c) be ascer-
tained to retain the same mediational relationships
(Greek letters in Fig. 1). Table 3, which presents a two-
by-two table where population and delivery system are
either fixed or different, summarizes levels that one
would ordinarily be willing to assert are needed to retain
evidentiary standards. Specifically, the upper left cell in-
volves traditional scaling-up, covering the situation
where the population and delivery system remain the
same. Sequential mediational equivalence for scaling-up
is often presumed to hold, so one would typically require
low levels of evidence for the means (Roman letters;
mostly levels 0 or 1), no need to reverify that the
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mediational relationships hold (Greek letters), and no
need to measure distal outcomes. For type I population
fixed, different delivery system scaling-out (upper right),
the mediational relationships are again expected to hold,
reach could be measured with a proxy, but because the
delivery system changes we would need stronger evi-
dence around implementation fidelity, adoption, and
sustainment. For type II delivery system fixed, different
population scaling-out (lower left), we would typically
want to assess reach with high accuracy due to the focus
on a new population, but may make the case that asses-
sing implementation fidelity, adoption, and sustainment
could be done with proxy measures. For type III scaling-
out where both population and service delivery are different
(bottom right), logic would require more empirical examin-
ation that the mediational pathways remain in this new
context compared to types I or II scaling-out. Potentially,
proxy measures could be used to assess these mediational
relationships, and generally some measures of the distal
health outcome would be required as well.
Turning such guidance on the levels of new knowledge
required, as presented above, into a rigorous system of
empirical evaluations for non-inferiority compared to pre-
vious findings, will require additional development and
explication of statistical methods that will be presented in
a follow-up paper. At the heart of the scale-out approach
is borrowing strength through the use of mediational
modeling. Mediational analysis has an extensive history
[74, 75] but has had increased interest in implementation
science [76]. Recent methodologic developments have ad-
dressed challenging issues in causality for single [77] and
multiple randomized trials [25], evolving interventions [12],
natural experiments [78, 79], and multilevel [78] as well as
multidimensional situations [80].
This proposed framework for implementation re-
search regarding scaling-out still leaves unanswered
details regarding how best to assess changes in the
complex implementation systems that we construct to
deliver EBIs. Major implementation strategy adapta-
tions often occur, and indeed are sometimes required
to support implementation in delivery systems with
widely different system and/or organizational cultures
and climates, readiness, and resources [81], to popula-
tions having widely different histories, norms and
values. Indeed, there is a recognition that equifinality
[82] is common in complex systems governing imple-
mentation. That is, there are multiple implementation
strategies that, in specific circumstances can effect-
ively address different barriers to implementation, as
well as the same barrier (e.g., financing) [83–85].
Nevertheless, it is likely that broad systems for meas-
uring implementation process through key milestones,
quality, and quantity, such as those identified in the
Stages of Implementation Completion [86–88], or similar
unobtrusive measures [89] can be used to measure
implementation fidelity and progress in diverse conditions.
Conclusion
To close this discussion of a framework for asserting that a
scaling-out is expected to share the original version’s impact
on health outcomes by relying on previous studies and new
empirical data, we note that more rapid implementation is
especially important to the delivery of effective interven-
tions to minorities and other populations experiencing
Table 3 Typical Levels of Evaluation Required when Population and/or Delivery System Change
SYSTEM
Domain
(mean, regression from Fig. 1)
Same Different
POPULATION
Same Scaling-Up Type I Scaling-Out: Population fixed,
different delivery system
Implementation Fidelity (a, α)
Intervention Fidelity (b, β)
Reach (c, γ)
Adoption (a, α)
Sustainment (a, α)
Health Outcome (d, e, δ)
a = 1–2, α = 0
b = 1–2, β = 0
c = 1, γ = 0
a = 1, α = 0
a = 1, α = 0
d, e = 0, δ = 0
a = 2, α = 0
b = 1–2, β = 0
c = 1, γ = 0
a = 2, α = 0
a = 2, α = 0
d, e = 0, δ = 0
Different Type II Scaling-Out: Delivery System Fixed,
different population
Type III Scaling-Out: Different Population
and Delivery System
Implementation Fidelity (a, α)
Intervention Fidelity (b, β)
Reach (c, γ)
Adoption (a, α)
Sustainment (a, α)
Health Outcome (d, e, δ)
a = 1,2, α = 0
b = 1–2, β = 0
c = 2, γ = 0
a = 1, α = 0
a = 1, α = 0
d, e = 0, δ = 0
a = 2, α = 1–2
b = 2, β = 1–2
c = 2, γ = 0
a = 1, α = 0
a = 1, α = 0
d, e = 2–3, δ = 0–3
Notes: Refer to Fig. 1 for definitions of Greek and Roman symbols
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health or health service disparities that would other-
wise not benefit from the extensive research required
to demonstrate effectiveness [90, 91].
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